

# **DURABILITY OF GENE THERAPY IN HAEMOPHILIA? BRIDGING TRIAL RESULTS WITH CLINICAL PRACTICE**

**EAHAD 2026, The Convention Centre Dublin,  
Dublin, Ireland**

**Wednesday 4 February, 2026 | 14:30–15:30**

**Room: Auditorium**



**Dr Dalia Khan (Chair)**

Haemophilia Centre,  
Oxford University Hospital,  
Oxford, United Kingdom



**Dr Jan Astermark**

Lund University and Skåne  
University Hospital,  
Malmö, Sweden



**Dr David Lillicrap**

Department of Pathology  
and Molecular Medicine,  
Queen's University,  
Kingston, Ontario, Canada



**Dr Glenn Pierce**

Vice President (Medical),  
World Federation  
of Hemophilia,  
Quebec, Canada

## **AGENDA**

<b>Welcome and Introduction</b> <i>Dr Dalia Khan</i>	<b>14:30–14:35</b>
<b>Evaluating Clinical Outcomes in Haemophilia: A Review of Current Data with a Focus on Haemophilia B</b> <i>Dr Jan Astermark</i>	<b>14:35–14:45</b>
<b>Gene Therapy Longevity: Bridging Preclinical Models to Clinical Reality</b> <i>Dr David Lillicrap</i>	<b>14:45–14:55</b>
<b>AAV Gene Therapy Guidelines: Why Now?</b> <i>Dr Glenn Pierce</i>	<b>14:55–15:05</b>
<b>Implementing Guidelines for Gene Therapy in Haemophilia</b> <i>Dr Dalia Khan</i>	<b>15:05–15:15</b>
<b>Closing Remarks and Adjourn</b> <i>Dr Dalia Khan</i>	<b>15:15–15:30</b>

This symposium is organised and funded by CSL. Company products will be discussed. Prescribing and adverse event reporting information will be available at the meeting.

MED-ALL-HGX-00336 | GL-HGX-0029 | January 2026